CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 101 enrolled
Drug / intervention
IQP-MM-101device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01969214
NCT01969214N/ACompleted

Open Label Study to Assess the Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea

InQpharm Group·interventional·Posted Oct 25, 2013·Updated Mar 4, 2020

In Brief

A clinical study evaluating IQP-MM-101 for Diarrhoea. Completed, enrolled 101 participants across 1 site.

Detailed Summary

Diosmectite in IQP-MM-101 has been used for diarrhoea control. Backed by data from several studies demonstrating their efficacy, the investigators are conducting this study to look into the efficacy and safety of IQP-MM-101 in diarrhoea control.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiarrhoea
CountriesGermany
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 25, 2013
Enrollment StartOct 1, 2013
Primary CompletionJun 1, 2014
Study CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 12.7 years ago

Interventions

IQP-MM-101device

Dissolve the effervescent tablets in half a glass of water, to be taken orally 1 tablet, 3 times a day